Qi Zeng is a Research Director at the A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), an Adjunct Professor at the Department of Biochemistry of the National University of Singapore (NUS), and the founder of Intra-ImmunSG Pte Ltd, an A*STAR spinoff company. Zeng carried out her undergraduate training in Xiamen University, China, and her PhD training at Roswell Park Comprehensive Cancer Center, US, and A*STAR IMCB. She was conferred her PhD degree by NUS in 1993.
Zeng’s team discovered PRL3 phosphatase and uncovered the mechanisms of PRL3 in driving cancer hallmarks. Her lab demonstrated that PRL1 and PRL3 monoclonal antibodies could inhibit experimental metastasis of cancer cells expressing these antigens and accordingly proposed and pioneered an unconventional approach of immunotherapy using monoclonal antibodies to target intracellular oncoproteins.
A*STAR spinoff biotech company Intra-ImmuSG is a Phase 2 clinical-stage biotechnology firm developing novel cancer therapies that target tumours with precision while minimising side effects for patients.
, an Adjunct Professor at the Department of Biochemistry of the National University of Singapore (NUS), and the founder of Intra-ImmunSG Pte Ltd, an A*STAR spinoff company. Zeng carried out her undergraduate training in Xiamen University, China, and her […]&picture=https://research.a-star.edu.sg/wp-content/uploads/2020/11/qi-zeng-1-e1759766398569.jpg)
